BSE filing, NSE: CRSTCHM. Summary written from the filing by ALFA Finder's alert engine.
Crestchem Ltd: key numbers
- Share price
- ₹142.75
- Market cap
- ₹42.82 Cr
- Revenue (annual)
- ₹29.61 Cr
- Net profit (annual)
- ₹2.71 Cr
- P/E (TTM)
- 12.8×Sector 34.1×
- Promoter holding
- 29.72%-0.04% QoQ
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Crestchem Ltd
All →Crestchem Board Meeting Date
Crestchem Limited will hold a board meeting on November 5, 2026 to approve unaudited standalone and consolidated results for the quarter and half year ended September 30, 2026. The agenda also allows other items with the Chair's permission.
Crestchem Price Movement Clarification
Crestchem Limited clarified that recent stock price movements are market-driven and not due to any undisclosed material information. The company confirmed compliance with all SEBI disclosure regulations.
Crestchem Other Announcement
Crestchem Ltd filed its quarterly shareholding pattern for the period ended September 30, 2026, in compliance with SEBI Regulation 31(1)(b).
Crestchem Promoter Selling: ₹0.03 Cr
Crestchem Ltd promoters reported market transactions on September 10, 2026. Director Dipak Patel acquired 981 shares while Sonalben Patel sold 1,000 shares.
- Value
- ₹0.03 Cr
Crestchem Promoter Buying
Promoter Dipak Narendraprasad Patel acquired 200 equity shares of Crestchem Ltd via market purchase for ₹0.0026 Crore.
Crestchem Other Announcement
Crestchem Limited issued duplicate share certificates to one shareholder for three lost certificates covering 100 shares. This is a routine administrative filing with no financial impact.
Other merger & restructuring announcements
All →Quint Digital Merger & Restructuring
Quint Digital's board approved a Rule 10b5-1 trading plan and the incorporation of a wholly owned overseas subsidiary. No investment amount was disclosed.
Hexaware Technologies Merger & Restructuring
Hexaware Technologies approved a slump sale of its step-down subsidiary Tech SMC Square India to Tech SMC Squared (GCC) India, a related-party deal. Consideration is cash, yet to be set by a registered valuer.
- Execution
- Expected completion by 30 June 2027; agreement date stated as 1 December 2026
Emkay Global Financial Services Merger & Restructuring Worth ₹2.75 Cr
Emkay Global agreed to sell its Wealth Management Business to a step-down subsidiary, Emkay Wealth Advisory, for Rs. 2.75 Crore cash. Completion is expected by 26 January 2027.
- Value
- ₹2.75 Cr
- Execution
- Completion expected by 26 January 2027
TVS Holdings Merger & Restructuring
TVS Holdings forwarded TVS Motor's board outcome of October 28, 2026 approving acquisition of Harita ARC and a composite scheme of amalgamation and demerger. The scheme is subject to stock exchange, SEBI, NCLT and shareholder approvals.
Emkay Global Financial Services Merger & Restructuring Worth ₹30 Cr
Emkay Global approved transferring two subsidiaries to new subsidiary ECPL and slump-selling its wealth business. Up to Rs.30 Crore rights investment in ECPL was also approved.
- Value
- ₹30.00 Cr
- Execution
- Divestment completion expected within 90 days of SPA execution, subject to regulatory approvals
Fortis Healthcare Merger & Restructuring Worth ₹277 Cr
Fortis subsidiary International Hospital acquired Suguna Ramaiah Hospitals' business, operations, land and building for Rs 277 Crore cash. The deal was consummated today, strengthening Bengaluru presence.
- Value
- ₹277.0 Cr